Endologix Inc. (NASDAQ:ELGX)’s share price traded down 2.6% during trading on Thursday . The stock traded as low as $11.62 and last traded at $11.62, with a volume of 439,992 shares. The stock had previously closed at $11.93.

Several equities analysts have recently commented on the stock. BMO Capital Markets restated a “buy” rating and set a $15.00 price target on shares of Endologix in a research report on Wednesday, August 3rd. BTIG Research restated a “buy” rating and set a $16.00 price target on shares of Endologix in a research report on Wednesday, August 3rd. Piper Jaffray Cos. restated an “overweight” rating and set a $15.00 price target on shares of Endologix in a research report on Wednesday, August 3rd. Oppenheimer Holdings Inc. set a $15.00 price target on shares of Endologix and gave the stock a “buy” rating in a research report on Wednesday, August 3rd. Finally, RBC Capital Markets lowered shares of Endologix from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $17.00 to $12.00 in a research report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. Endologix presently has an average rating of “Buy” and a consensus price target of $13.86.

The firm’s 50 day moving average price is $13.15 and its 200 day moving average price is $10.74. The firm’s market capitalization is $955.52 million.

Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.07. The company had revenue of $51 million for the quarter, compared to the consensus estimate of $46.30 million. The firm’s revenue was up 29.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.18) earnings per share. On average, analysts anticipate that Endologix Inc. will post ($0.74) earnings per share for the current fiscal year.

In other news, President Robert D. Mitchell sold 2,294 shares of the firm’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $12.55, for a total value of $28,789.70. Following the completion of the sale, the president now directly owns 318,233 shares in the company, valued at $3,993,824.15. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John D. Mcdermott sold 6,116 shares of the firm’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $12.55, for a total value of $76,755.80. Following the completion of the sale, the chief executive officer now owns 663,624 shares of the company’s stock, valued at $8,328,481.20. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Endologix stock. New York State Common Retirement Fund raised its position in shares of Endologix Inc. (NASDAQ:ELGX) by 134.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,020 shares of the company’s stock after buying an additional 85,920 shares during the period. New York State Common Retirement Fund owned 0.22% of Endologix worth $1,485,000 at the end of the most recent reporting period.

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.